Vimarsana
Biggest News Aggregation in the World

Osteosarcoma Collaborative News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Osteosarcoma Collaborative. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Osteosarcoma Collaborative Today - Breaking & Trending Today

Column: Father recalls anonymous donation of $50,000 that helped save his son's life: 'Miracles really do occur' - Vimarsana News

Column: Father recalls anonymous donation of $50,000 that helped save his son's life: 'Miracles really do occur'

When the email came in from Juan Romero asking that I give him a call, I have to admit I did so with some apprehension. The last time I had spoken with him, in February 2017, the Aurora, Illinois, father was desperate: His then-9-year-old son, Carlos, was battling a rare and deadly bone cancer that tends to hit children and young adults. And he was struggling to come up with the money needed ...

Source: yahoo.com
Column: Aurora father recalls anonymous donation of $50,000 that helped save his son's life: 'Miracles really do occur' - Vimarsana News

Column: Aurora father recalls anonymous donation of $50,000 that helped save his son's life: 'Miracles really do occur'

When the email came in from Juan Romero asking that I give him a call, I have to admit I did so with some apprehension. The last time I had spoken with him, in February 2017, the Aurora father was desperate: His then-9-year-old son, Carlos, was battling a rare and deadly bone cancer that tends to hit children and young adults. And he was struggling to come up with the money needed for an ...

Source: yahoo.com
OS Therapies Announces Nationwide Open Enrollment of Remaining 36 to 42 Patients in Phase IIb Trial of OST-HER2 (Listeria monocytogenes) in Recurred, Resected Osteosarcoma - Vimarsana News

OS Therapies Announces Nationwide Open Enrollment of Remaining 36 to 42 Patients in Phase IIb Trial of OST-HER2 (Listeria monocytogenes) in Recurred, Resected Osteosarcoma

/PRNewswire/ -- OS Therapies, a research and clinical-stage biopharmaceutical company announced today that the Data Safety & Monitoring Committee (DSMC)...